CARB-X FUNDS GSK TO DEVELOP A NEW DRUG FOR URINARY TRACT INFECTIONS (UTI) CAUSED BY ESCHERICHIA COLI BACTERIA

  23 September 2020

CARB-X announced today it is awarding up to US$7.51 million to GlaxoSmithKline (NYSE: GSK), to develop a new drug to treat and prevent recurrent urinary tract infections (UTIs) caused by the Escherichia coli (E. coli) bacteria.

“Serious bacterial infections are a global health threat, due in part to the emergence of drug-resistant bacteria for which we do not have therapies,” said Erin Duffy, CARB-X R&D Chief.  “GSK’s project is in the early stages of development, and if successful, could potentially treat and prevent recurrent UTIs caused by E. coli and stop harmful bacteria from spreading in the body.”

UTIs are among the most frequent bacterial infections. UTIs occur when bacteria from the skin or periurethral area enter the urethra and infect the urinary tract and bladder. More women than men develop these infections, at a ratio of 8:1. An estimated 40-50 per cent of women will develop a UTI in their lifetime.

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

Register

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed